TITLE

thiazolidinediones

AUTHOR(S)
Peters, Michael
PUB. DATE
June 2004
SOURCE
BMA A-Z Family Medical Encyclopedia;2004, p740
SOURCE TYPE
Book
DOC. TYPE
Reference Entry
ABSTRACT
An encyclopedia entry for "thiazolidinediones" is presented. It pertains to a group of oral hypoglycaemics that are utilized in the treatment of type 2 diabetes mellitus. Thiazolidinedione is sometimes pertained as glitazones. It functions by cutting the body cells' resistance to insulin and are usually administered with metformin.
ACCESSION #
44001254

 

Related Articles

  • Metformin: A Review of Its Use in the Treatment of Type 2 Diabetes. Papanas, N.; Maltezos, E. // Clinical Medicine: Therapeutics;2009, Issue 1, p1367 

    Metformin is now the most widely prescribed oral hypoglycemic agent. This review outlines its use in the treatment of type 2 diabetes. The main mechanisms of action include reduction of appetite and of intestinal carbohydrate absorption, inhibition of hepatic gluconeogenesis, and increased...

  • CLINICAL ROUNDS: Medications in Diabetes Management. Wilchowski, Sara; Waack, Stacy; Levine, Shel // Clinical Kinesiology (Online Edition);Winter2007, p25 

    No abstract available.

  • Thiazolidinediones and Type 2 Diabetes: From Cellular Targets to Cardiovascular Benefit. Papaetis, Georgios S.; Orphanidou, Dora; Panagiotou, Themistoklis N. // Current Drug Targets;Sep2011, Vol. 12 Issue 10, p1498 

    No abstract available.

  • Integrated lipidomics and transcriptomic analysis of peripheral blood reveals significantly enriched pathways in type 2 diabetes mellitus. Chen Zhao; Jinghe Mao; Junmei Ai; Ming Shenwu; Tieliu Shi; Daqing Zhang; Xiaonan Wang; Yunliang Wang; Youping Deng // BMC Medical Genomics;2013, Vol. 6 Issue Suppl 1, p1 

    Background: Insulin resistance is a key element in the pathogenesis of type 2 diabetes mellitus. Plasma free fatty acids were assumed to mediate the insulin resistance, while the relationship between lipid and glucose disposal remains to be demonstrated across liver, skeletal muscle and blood....

  • Short Insulin Tolerance Test May Determine Thiazolidinediones Treatment in Type 2 Diabetes. Lee, Mi Y.; Koh, Jang H.; Jung, Pil M.; Shim, Myoung S.; Kim, Mi J.; Shin, Jang Y.; Shin, Young G.; Chung, Choon H. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA578 

    The short insulin tolerance test is a simple and reliable method of estimating insulin sensitivity. This study was designed to compare the insulin sensitizing effects of thiazolidinediones (TZDs) on the degree of insulin resistance determined by short insulin tolerance test, Kitt in type 2...

  • SCREENING FOR PPAR γ AGONIST FROM MYRISTICA FRAGRANS HOUTT SEEDS FOR THE TREATMENT OF TYPE 2 DIABETES BY IN VITRO AND IN VIVO. LESTARI, KERI; J. K. HWANG; KARIADI, SRI HARTINI; WIJAYA, ANDI; AHMAD, TRIHANGGONO; SUBARNAS, ANAS; SUPRIYATNA; MUCHTARIDI, M. // Medical & Health Science Journal;2012, Vol. 12 Issue 3, p7 

    In general, a type two diabetes mellitus (T2DM) patient suffers for hyperglycaemia and insulin resistance. Nowadays, there is an anti diabetes drug working as a PPARγ/α agonist and has a significant effect to improve the hyperglycemia and insulin resistance condition. However, this drug...

  • pioglitazone. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p609 

    An encyclopedia entry for "pioglitazone" is presented. It is an oral hypoglaecemic drug used in combination with other hypoglaecemics in the treatment of type 2 diabetes mellitus. It acts by reducing resistance to insulin in the body tissues. among its side effects include gastrointestinal...

  • Evaluation of Guideline Recommendations on Oral Medications for Type 2 Diabetes Mellitus. Bennett, Wendy L.; Odelola, Olaide A.; Wilson, Lisa M.; Bolen, Shari; Selvaraj, Saranya; Robinson, Karen A.; Bass, Eric B.; Puhan, Milo A. // Annals of Internal Medicine;1/3/2012, Vol. 156 Issue 1, p27 

    Background: Clinical practice guidelines have an important role in guiding choices among the numerous medications available to treat type 2 diabetes mellitus, but little is known about their quality. Purpose: To assess whether guidelines on oral medications for type 2 diabetes are consistent...

  • Meeting glycemic goals: Options beyond metformin. DeBenederte, Valerie // Drug Topics;Nov2012 Supplement, p8s 

    The article discusses the options in drug treatment for type 2 diabetes patients beyond the use of metformin in controlling glycemic and glycosylated hemoglobin (HbA1c) levels. Clinical professor Stefanie C. Nigro explains that approaches in diabetes management and patient care plan may differ...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics